We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |


Alfred Jay Bollet, M.D.; Roger Black, M.D.; Joseph J. Bunim, M.D.
JAMA. 1955;158(6):459-463. doi:10.1001/jama.1955.02960060017005.
Text Size: A A A
Published online


Two new synthetic steroids, prednisolone and prednisone, formerly known as metacortandralone and metacortandracin, respectively, have recently been introduced as antirheumatic agents in rheumatoid arthritis.1 They have been found to be four times more potent than cortisone in suppressing the inflammatory joint changes produced by the disease. They also cause depletion of the circulating eosinophils and significant reduction of urinary 17-ketosteroid excretion. In contrast to cortisone, administration of the new steroids is not associated with sodium and water retention or with potassium loss. Early experience with the new steroids revealed the occurrence of minor undesirable side-effects, such as facial rounding, hirsutism, diminished carbohydrate tolerance, insomnia, restlessness, weakness, transitory mental clouding, acne, increased skin pigmentation, and vague abdominal distress.

The purpose of this paper is to report three cases of major undesirable side-effects that occurred in a series of 18 successive cases of rheumatoid arthritis treated with prednisolone or prednisone. A


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.